{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-105839","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.159085+00:00","generated_at":"2026-05-17T16:45:47.727669+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Surrozen Q2 2025 net income $39.7M on non-cash gains; cash $90.4M, appoints new clinical VP","bullets":["Net income of $39.7M ($2.55/diluted share) versus net loss of $25.3M in Q2 2024; driven by non-cash gains on tranche liability and warrant revaluation.","Cash and cash equivalents $90.4M at June 30, 2025, down from $101.6M at March 31, 2025.","Appointed Daniel Chao, M.D., Ph.D., as VP and Head of Clinical Development; also formed Clinical Advisory Board with four retinal specialists.","Granted U.S. Patent No. 12,297,278 covering SWAP multi-specific Wnt surrogate technology; IND submission for SZN-8141 targeted for 2026.","R&D expenses $6.0M (up from $5.3M) and G&A $4.0M (up from $3.7M); research service revenue from related party $1.0M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-105839","json":"https://secwatch.observer/filing/0000950170-25-105839.json","markdown":"https://secwatch.observer/filing/0000950170-25-105839.md","text":"https://secwatch.observer/filing/0000950170-25-105839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017025105839/0000950170-25-105839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017025105839/srzn-20250808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:45:47.727669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}